Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03953417 · ClinicalTrials.gov registry record · NA

Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression

A NA study of Treatment-Resistant Depression, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
7
Enrollment target
1
Study location

NCT03953417 is a NA study of Treatment-Resistant Depression that has completed, run by Stanford University. The registered enrollment target is 7 participants, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03953417, a NA study of Treatment-Resistant Depression, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant bipolar depression. In this open-label study, all participants will receive accelerated theta-burst stimulation.

Interventions

  • DEVICE Accelerated intermittent theta-burst treatment

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-07-01
Est. Completion 2023-12-30
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT03953417

The ClinicalTrials.gov registry entry for NCT03953417 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (98% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Accelerated intermittent theta-burst treatment is the first listed.

NCT03953417 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03953417 about?

NCT03953417 is a clinical study titled "Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression". This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant bipolar depression. In this open-label study, all participants will receive accelerated theta-burst stimulation.

What is the current status of trial NCT03953417?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2019-07-01. Estimated completion is 2023-12-30.

What conditions does trial NCT03953417 study?

This clinical trial studies the following conditions: Treatment-Resistant Depression.

What interventions are being tested in trial NCT03953417?

The interventions under investigation include: Accelerated intermittent theta-burst treatment (DEVICE).

Who is sponsoring clinical trial NCT03953417?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03953417 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Treatment-Resistant Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.